Intuitive Surgical, Inc. (ISRG) AI Stock Analysis

Intuitive Surgical, Inc. specializes in developing, manufacturing, and globally distributing medical products for minimally invasive healthcare. Established in 1995 and headquartered in Sunnyvale, California, the company is known for its flagship da Vinci Surgical System, which facilitates complex procedures through minimally invasive techniques. Intuitive also offers the Ion endoluminal system for diagnostic procedures, enabling minimally invasive biopsies in the lung and other vital areas. In addition, the company provides stapling, energy, and core instrumentation to complement its platforms. Intuitive supports healthcare providers with integrated digital capabilities, training pathways, and comprehensive customer services including installation, repair, and ongoing maintenance.

Between FY2021 and FY2025, Intuitive expanded annual revenue from $5.71B to $10.06B, reflecting a 5-year revenue CAGR of 18.2%. Revenue grew 31.0% in FY2021, 9.0% in FY2022, 14.5% in FY2023, 17.2% in FY2024, and 20.5% in FY2025. Annual net income increased from $1.70B in FY2021 to $2.86B in FY2025, while EPS climbed from $4.97 to $8.93. Gross margin was 66.0% and operating margin was 29.3% in FY2025. Over the trailing twelve months, revenue reached $11.03B with an operating margin of 33.6%. In the latest quarter ended June 30, 2026, quarterly revenue grew 18.5% year-over-year while quarterly earnings grew 26.5%.

As of June 30, 2026, Intuitive held $5.22B in cash and short-term investments, total assets of $20.88B, and shareholders' equity of $18.17B. The company maintained a current ratio of 4.96. In FY2025, operating cash flow reached $3.03B and free cash flow stood at $2.49B, supporting $539.8M in capital expenditures. Intuitive also allocated $2.30B to share buybacks in FY2025, contributing to a 5-year share count change of -2.4%.

At a last close of $426.70, Intuitive trades at a trailing P/E of 48.9x and a forward P/E of 33.3x, both above the median of its Nasdaq-100 Healthcare peers of 28.9x and 19.7x. Its price-to-sales of 13.7x and EV/EBITDA of 32.2x also exceed peer medians of 6.5x and 20.9x. The stock has delivered a 1-year return of -1.8% and a 5-year return of 28.7%, trailing the S&P 500 (SPY) returns of 16.8% and 83.0% over the same periods.

Wall Street analysts hold 18 Strong Buy, 8 Buy, 7 Hold, 0 Sell, and 1 Strong Sell ratings on the stock. The mean price target is $478.53, which is 12.1% above the last close of $426.70. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $11.76B and EPS of $10.80, representing 20.9% EPS growth. Intuitive beat EPS estimates in each of the last 4 quarters, with its next earnings date scheduled for October 20, 2026.

This page is an AI-written research summary of Intuitive Surgical, Inc. (ISRG). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ISRG income statement, ISRG balance sheet, ISRG key metrics, ISRG analyst forecast, ISRG chart. See the ISRG stock overview for the latest quote and news.